DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 6,585,967 B2 Narang Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 6,585,967 B2 Narang Et Al USOO6585967B2 (12) United States Patent (10) Patent No.: US 6,585,967 B2 Narang et al. (45) Date of Patent: *Jul. 1, 2003 (54) ADHESIVE TREATMENT FORTINEA 5,480,935 A 1/1996 Greff et al. CRURIS 5,514,371 A 5/1996 Leung et al. 5,514,372 A 5/1996 Leung et al. Inventors: Upvan Narang, Raleigh, NC (US); 5.530,037 A 6/1996 McDonnell et al. (75) 5,554,365 A 9/1996 Byram et al. William S. C. Nicholson, Raleigh, NC 5,575.997 A 11/1996 Leung et al. (US); Anthony Sherbondy, Raleigh, 5,580,565 A 12/1996 Tighe et al. NC (US); Gabriel N. Szabo, Raleigh, 5,582,834 A 12/1996 Leung et al. NC (US) 5,613,942 A 3/1997 Lucast et al. 5,624,669 A 4/1997 Leung et al. (73) Assignee: Closure Medical Corporation, 5,653,769 A 8/1997 Barley, Jr. et al. Raleigh, NC (US) 5,661,170 A 8/1997 Chodosh ..................... 514/390 5,665,817 A 9/1997 Greff et al. (*) Notice: Subject to any disclaimer, the term of this 5,684,042 A 11/1997 Greff et al. patent is extended or adjusted under 35 5,716,607 A 2/1998 Byram et al. U.S.C. 154(b) by 0 days. 5,716,608 A 2/1998 Byram et al. 5,717.005 A 2/1998 Richardson 5,725,491 A 3/1998 Tipton et al. This patent is Subject to a terminal dis 5,730,994. A 3/1998 Askill et al. claimer. 5,753,699 A 5/1998 Greff et al. 5,755,680 A 5/1998 Ghodsian (21) Appl. No.: 09/898,005 5,762.919. A 6/1998 Greff et al. 5,762.955 A 6/1998 Smith (22) Filed: Jul. 5, 2001 5,783,177 A 7/1998 Greff et al. 5,800,373 A 9/1998 Melanson et al. (65) Prior Publication Data 5,800,831 A 9/1998 Burnett et al. US 2003/000794.6 A1 Jan. 9, 2003 5,807,563 A 9/1998 Askill et al. 5,811,091 A 9/1998 Greff et al. (51) Int. Cl." .......................... A61K 31/74; A61K 7/00; 5,811,107 A 9/1998 Gangadharan et al. A61K 31/415 5,827,870 A 10/1998 Chodosh U.S. Cl. ..................... 424/78.31; 424/401; 514/390 5,840,072 A 11/1998 Carey (52) 5,855,208 A 1/1999 Askill et al. (58) Field of Search .............................. 424/401, 78.31; 5,981,621 A 11/1999 Clark et al. 514/390 6,001,345 A 12/1999 Askill et al. 6,086,906. A 7/2000 Greff et al. (56) References Cited 6,090,397 A 7/2000 Lee et al. 6,102.205 A 8/2000 Greff et al. U.S. PATENT DOCUMENTS 6,155,265 A 12/2000 Hammerslag 3,577,516 A 5/1971 Gould et al. 6,183,190 B1 2/2001 Raiteri 3,847,155 A 11/1974 Bernaola 6,183,593 B1 2/2001 Narang et al. 3,880,158 A 4/1975 Gurney 6,238,692 B1 5/2001 Smith 3.987,000 A 10/1976 Gleichenhagen et al. 6,433,096 B1 8/2002 Hickey et al. 4,073,291 A 2/1978 Marvel et al. 2001/0038857 A1 11/2001 Smith 4,287.177 A 9/1981 Nakashima et al. 2001/0051179 A1 12/2001 Berman 4,310,509 A 1/1982 Berglund et al. FOREIGN PATENT DOCUMENTS 4,323,557 A 4/1982 Rosso et al. 4,479,933 A 10/1984 Akimova et al. WO WO OO/35276 6/2000 4,560,555 A 12/1985 Snider WO WO O1/32795 A1 5/2001 4,643,180 A 2/1987 Feld et al. 4,752.472 A 6/1988 Kligman * cited by examiner 4,806,614 A 2/1989 Matsuda et al. Primary Examiner Thurman K. Page 4,826,677 A 5/1989 Mueller et al. 4,880,416 A 11/1989 Horiuchi et al. Assistant Examiner Blessing Fubara 4.913,897 A 4/1990 Chvapil et al. (74) Attorney, Agent, or Firm-Oliff & Berridge, PLC 4,981,483 A 1/1991 Akimova et al. (57) ABSTRACT 4,987,893 A 1/1991 Salamone et al. 5,009.224 A 4/1991 Cole A method of treating or preventing tinea cruris, commonly 5,082,663 A 1/1992 Konishi et al. known as Jock Itch, includes applying a polymerizable 5,103,812 A 4/1992 Salamone et al. 5,160.737 A * 11/1992 Friedman et al. ........... 424/401 monomer adhesive composition to an area of skin afflicted 5,254,132 A 10/1993 Barley et al. with or Susceptible to tinea cruris, optionally with at least 5,306,490 A 4/1994 Barley, Jr. one of an additional anti-fungal agent or a skin care additive, 5,320.838 A 6/1994 Woller and allowing the polymerizable monomer composition to 5,403.591 A 4/1995 Tighe et al. polymerize to form a polymer film over the area of Skin. 5,409,903 A 4/1995 Polak et al. 5,413,780 A 5/1995 Huprich 34 Claims, No Drawings US 6,585,967 B2 1 2 ADHESIVE TREATMENT FORTINEA drugs, Such as anti-fungal agents, to affected parts of the CRURIS skin. U.S. Pat. Nos. 5,716,607 and 5,716,608, both to Byram et al., disclose the use of cyanoacrylate adhesives to prevent ionization radiation damage to skin. Such damage is pre BACKGROUND OF THE INVENTION vented by applying the cyanoacrylate polymer to the skin to be protected. U.S. Pat. No. 5,653,769 to Barkey, Jr., et al., 1. Field of Invention discloses protecting skin areas from irritation due to contact The present invention relates to treatment and prevention with artificial devices Such as prosthetics, bandages and of tinea cruris, commonly known as Jock Itch. casts by applying a cyanoacrylate polymer to the desired 2. Description of Related Art skin areas that otherwise would be prone to ulceration or Monomer and polymer adhesives are used in both indus irritation by the devices. trial (including household) and medical applications. U.S. Pat. No. 4,287.177 to Nakashima et al. discloses a Included among these adhesives are the 1,1-disubstituted protective covering material for forming a film or coat on the ethylene monomers and polymers, Such as the skin or wound Surface, wherein the film may contain an C-cyanoacrylates. Since the discovery of the adhesive prop 15 anti-fungal agent that is controllably released when the erties of Such monomers and polymers, they have found composition is placed in contact with the skin. U.S. Pat. Nos. wide use due to the Speed with which they cure, the Strength 5,684,042; 5,753,699; 5,762,919; 5,783,177; and 5,811,091 of the resulting bond formed, and their relative ease of use. to Greffet al. disclose a cyanoacrylate composition with a These characteristics have made the C-cyanoacrylate adhe compatible anti-fungal agent to form an anti-fungal poly Sives the primary choice for numerous applications Such as meric cyanoacrylate film to be applied on mammalian skin bonding plastics, rubbers, glass, metals, Wood, and, more as wound dressings, wound bandages, Surgical incise drapes, recently, biological tissues. wound closure materials and the like. It is known that monomeric forms of C-cyanoacrylates are Tinea cruris, also referred to generally as jock itch or extremely reactive, polymerizing rapidly in the presence of ringworm of the groin, is a fungal infection or dermatophy even minute amounts of an initiator, including moisture 25 tosis of the groin, perineum and perineal regions, generally present in the air or on moist Surfaces Such as animal Seen in males, and Sometimes spreading to contiguous areas, (including human) tissue. Monomers of C-cyanoacrylates generally caused by fungal Species Such as those of are anionically polymerizable or free radical polymerizable, MicroSporum, Trichophyton, and Epidermophyton, particu or polymerizable by Zwitterions or ion pairs to form poly larly by the fungal Species of Trichophyton and Epidermo mers. Once polymerization has been initiated, the cure rate phyton. The condition generally includes Severely pruritic, can be very rapid. Sharply demarcated lesions with a raised erythematous mar Medical applications of 1,1-disubstituted ethylene adhe gin and thin, dry Scaling. Tinea cruris often accompanies Sive compositions include use as an alternate or an adjunct tinea pedis, or Athlete’s Foot. to Surgical Sutures and/or Staples in wound closure, as well Physicians commonly prescribe medications in the form as for covering and protecting Surface wounds Such as 35 of powders, aeroSols, liquids or creams for the treatment of lacerations, abrasions, burns, Stomatitis, Sores, minor cuts tinea cruris. Such medications are also commonly obtained and Scrapes, and other wounds. When an adhesive is applied by individuals “over-the-counter” for treatment of the same to Surfaces to be joined, it is usually applied in its mono skin condition. The source of the affliction often is a public meric form, and the resultant polymerization gives rise to the Safety and health concern, as the occurrence of tinea cruris desired adhesive bond. 40 is higher in public areas Such as locker rooms, public U.S. Pat. Nos. 5,514,371, 5,514,372, 5,575,997, 5,624, showers, Sports facilities, and the like. 669, and 5,582,834 to Leung et al. disclose the addition of Often the condition occurs on the skin areas of the groin, a therapeutic agent in a cyanoacrylate composition.
Load more

Recommended publications
  • Influence of Additives and Storage Temperature on Physicochemical and Microbiological Properties of Eye Drops Containing Cefazolin
    Acta Poloniae Pharmaceutica ñ Drug Research, Vol. 63 No. 3 pp. 225ñ234, 2006 ISSN 0001-6837 Polish Pharmaceutical Society PHARMACEUTICAL TECHNOLOGY INFLUENCE OF ADDITIVES AND STORAGE TEMPERATURE ON PHYSICOCHEMICAL AND MICROBIOLOGICAL PROPERTIES OF EYE DROPS CONTAINING CEFAZOLIN. ANNA KODYM 1, TOMASZ ZAWISZA 2, KAMILA BUèKA 2 and HELENA KUKU£A 3 1 Department of Drug Form Technology, Nicolaus Copernicus University Collegium Medicum in Bydgoszcz, 2 Department of Drug Form Technology, 3 Department of Pharmaceutical Bacteriology; K. Marcinkowski University of Medical Sciences in PoznaÒ Abstract: The purpose of the studies was to choose additives for eye drops containing cefazolin and the assess- ment of the influence of used additives and the storage temperature on the physicochemical properties and the stability of the eye drops. The drops were 1% sterile solutions of cefazolin in citrate buffer of pH 6.15-6.20. The drops were preserved with 0.002% thiomersal or 0.001% phenylmercuric borate mixed with 0.4% β- phenylethyl alcohol. Viscosity of the eye drops was increased using polyvinyl alcohol (PVAL). The pharma- ceutical compatibility test of selected additives with cefazolin showed the pharmaceutical interaction of 1% solution of cefazolin with higher than 0.003% concentration of thiomersal, 0.005% benzalkonium chloride and 0.01% chlorhexidine diacetate. The drops, protected from light, were stored at the temperature of 4∞C and 20∞C. As the criteria of the qualitative assessment of freshly prepared drops and during their storage, the following properties were considered: organoleptic analysis, sterility, pH, osmotic pressure, density, viscosity, antimicro- bial activity of cefazolin and preservation efficiency of thiomersal and phenylmercuric borate in the eye drops.
    [Show full text]
  • Subject Index
    52_1107_1136_SI 16.11.2005 9:35 Uhr Seite 1107 Subject Index A – tape 264, 368, 940 α-adjustment 154 AAS, see atomic absorption spectrophotometry adrenocorticotrophic hormone (ACTH) 21 abietic acid 909, 943 adverse drug reaction 401 abrasion 174, 283 aeroallergen 391 absorption through appendage 169 – atopic eczema 391 α-acaridial 329 – avoidance 391 accident 889 aerospace 726 acebutolol hydrochloride 909 African aceclofenac 909 –ebony783 acetaldehyde 943 – mahagony 783 acetone 118, 666 – red padauk wood 783 acetylacetone 697 Agave acetylsalicylic acid 84, 909 – americana 354 Achillea millefolium (yarrow extract) 909 – tequilana 225 aciclovir 909 age 279 acid 110 agent orange 806 – black 48 (CI 65005) 909 AGEP 404 – dye 689 Agfa TSS 355 – halogenated 259 aggravation 204 –hydrochloric261 agricultural worker 272 –nitric261 agriculture 725 –red AICD, see activation-induced cell death – – 14 (azorubine) 909 airborne – – 118 (CI 26410) 909 – allergic contact dermatitis 218, 228, 315, 467, 477, 484, 598, ––359909 627, 654, 788 – violet 17 (CI 42650) 909 – contact urticaria 753, 758 – yellow – irritant contact dermatitis 625 – – 36 (CI 13065, metanil yellow) 909 aircraft manufacture 560 – – 61 (CI 18968) 909 airway symptom 520 acitretin 341 alachlor 953 acneiform alantolactone 55, 789, 909, 954 – folliculitis 229 alclometasone-17,21-dipropionate 909 –lesion265 alclometasone-17-propionate 58 acrodermatitis enteropathica 241 alcohol, see also ethyl 909 acrovesicular dermatitis 401 aldehyde 110, 607, 886 acrylamide 592, 944 algicide 562 acrylate
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Selling Mercury Cosmetics and Pharmaceuticals (W-Hw4-22)
    www.pca.state.mn.us Selling mercury cosmetics and pharmaceuticals Mercury-containing skin lightening creams, lotions, soaps, ointments, lozenges, pharmaceuticals and antiseptics Mercury is a toxic element that was historically used in some cosmetic, pharmaceutical, and antiseptic products due to its unique properties and is now being phased out of most uses. The offer, sale, or distribution of mercury-containing products is regulated in Minnesota by the Minnesota Pollution Control Agency (MPCA). Anyone offering a mercury-containing product for sale or donation in Minnesota is subject to these requirements, whether a private citizen, collector, non-profit organization, or business. Offers and sales through any method are regulated, whether in a store or shop, classified advertisement, flea market, or online. If a mercury-containing product is located in Minnesota, it is regulated, regardless of where a purchaser is located. Note: This fact sheet discusses the requirements and restrictions of the MPCA. Cosmetics and pharmaceuticals may also be regulated for sale whether they contain mercury or not by other state or federal agencies, including the Minnesota Board of Pharmacy and the U.S. Food & Drug Administration. See More information on page 2. What are the risks of using mercury-containing products? Use of mercury-containing products can damage the brain, kidneys, and liver. Children and pregnant women are at increased risk. For more information about the risks of mercury exposure, visit the Minnesota Department of Health. See More information on the page 2. If you believe you have been exposed to a mercury-containing product, contact your health care provider or the Minnesota Poison Control Center at 1-800-222-1222.
    [Show full text]
  • Topical and Systemic Antifungal Therapy for Chronic Rhinosinusitis (Protocol)
    CORE Metadata, citation and similar papers at core.ac.uk Provided by University of East Anglia digital repository Cochrane Database of Systematic Reviews Topical and systemic antifungal therapy for chronic rhinosinusitis (Protocol) Head K, Sacks PL, Chong LY, Hopkins C, Philpott C Head K, Sacks PL, Chong LY, Hopkins C, Philpott C. Topical and systemic antifungal therapy for chronic rhinosinusitis. Cochrane Database of Systematic Reviews 2016, Issue 11. Art. No.: CD012453. DOI: 10.1002/14651858.CD012453. www.cochranelibrary.com Topical and systemic antifungal therapy for chronic rhinosinusitis (Protocol) Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 BACKGROUND .................................... 1 OBJECTIVES ..................................... 3 METHODS ...................................... 3 ACKNOWLEDGEMENTS . 8 REFERENCES ..................................... 9 APPENDICES ..................................... 10 CONTRIBUTIONSOFAUTHORS . 25 DECLARATIONSOFINTEREST . 26 SOURCESOFSUPPORT . 26 NOTES........................................ 26 Topical and systemic antifungal therapy for chronic rhinosinusitis (Protocol) i Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. [Intervention Protocol] Topical and systemic antifungal therapy for chronic rhinosinusitis Karen Head1, Peta-Lee Sacks2, Lee Yee Chong1, Claire Hopkins3, Carl Philpott4 1UK Cochrane Centre,
    [Show full text]
  • THE INFLUENCE of SOME ANTIFUNGAL ANTIBIOTICS on NEUROMUSCULAR TRANSMISSION B.L
    THE INFLUENCE OF SOME ANTIFUNGAL ANTIBIOTICS ON NEUROMUSCULAR TRANSMISSION B.l M. SIRSI Pharmacology Laboratory, Indian Institute of Science, Bangalore, 12. (Received January 25, 1963) The influcncc of the polyene antifungal antibiotics pimaricin, amphotericin A and B and nystatin, on neuromuscular transmission has been studied. In presence of these antibiotics both direct and indirect electrical stimulation is found. to cause varying degrees of contracture and diminished excitability of the musculature. This is in contrast to the effect of Hamycin, another polyene antibiotic which produces loss of excitability without any initial contracture of the diaphragm. Certain antibiotics have been shown to produce neuromuscular block, both in experimental animals and in humaps. Intraperitoneal administra- tion of neomycin has been followed by respiratory insufficiency or apnoea; streptomycin has caused neuromuscular block in experimental animals and in interccstal nerve preparations of human and is strongly incriminated in causing the muscular weakness and visual difficulty as also post-operative paralysis by neuromuscular blockage (Fisk, 1961, Bush, 1961). Polymyxin B is also reported to exhibit blocking action on the muscle end plate (Sabawala and Dillon, 1959). The following communication deals with the effect of certain antifungal antibiotics on the neuromuscular junction as studied by the rat phrenic nerve diaphragm preparations. METHODS The antibiotics studied were, pimaricin, amphotericin A and B, and nystatin. Their effects have been compared with those of hamycin reported earlier (Sirsi, 1963). -- The required concentrations of the antibiotics were prepared in propylene glycol and further dilutions in water. Phrenic nerve diaphragm preparations were made as described by Bulbring (1916) and were suspended in abath of 75 ml of aerated Tyrode's solution which contained twice the amount of glucose as stated in original M.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Aldrich Organometallic, Inorganic, Silanes, Boranes, and Deuterated Compounds
    Aldrich Organometallic, Inorganic, Silanes, Boranes, and Deuterated Compounds Library Listing – 1,523 spectra Subset of Aldrich FT-IR Library related to organometallic, inorganic, boron and deueterium compounds. The Aldrich Material-Specific FT-IR Library collection represents a wide variety of the Aldrich Handbook of Fine Chemicals' most common chemicals divided by similar functional groups. These spectra were assembled from the Aldrich Collections of FT-IR Spectra Editions I or II, and the data has been carefully examined and processed by Thermo Fisher Scientific. Aldrich Organometallic, Inorganic, Silanes, Boranes, and Deuterated Compounds Index Compound Name Index Compound Name 1066 ((R)-(+)-2,2'- 1193 (1,2- BIS(DIPHENYLPHOSPHINO)-1,1'- BIS(DIPHENYLPHOSPHINO)ETHAN BINAPH)(1,5-CYCLOOCTADIENE) E)TUNGSTEN TETRACARBONYL, 1068 ((R)-(+)-2,2'- 97% BIS(DIPHENYLPHOSPHINO)-1,1'- 1062 (1,3- BINAPHTHYL)PALLADIUM(II) CH BIS(DIPHENYLPHOSPHINO)PROPA 1067 ((S)-(-)-2,2'- NE)DICHLORONICKEL(II) BIS(DIPHENYLPHOSPHINO)-1,1'- 598 (1,3-DIOXAN-2- BINAPH)(1,5-CYCLOOCTADIENE) YLETHYNYL)TRIMETHYLSILANE, 1140 (+)-(S)-1-((R)-2- 96% (DIPHENYLPHOSPHINO)FERROCE 1063 (1,4- NYL)ETHYL METHYL ETHER, 98 BIS(DIPHENYLPHOSPHINO)BUTAN 1146 (+)-(S)-N,N-DIMETHYL-1-((R)-1',2- E)(1,5- BIS(DI- CYCLOOCTADIENE)RHODIUM(I) PHENYLPHOSPHINO)FERROCENY TET L)E 951 (1,5-CYCLOOCTADIENE)(2,4- 1142 (+)-(S)-N,N-DIMETHYL-1-((R)-2- PENTANEDIONATO)RHODIUM(I), (DIPHENYLPHOSPHINO)FERROCE 99% NYL)ETHYLAMIN 1033 (1,5- 407 (+)-3',5'-O-(1,1,3,3- CYCLOOCTADIENE)BIS(METHYLD TETRAISOPROPYL-1,3- IPHENYLPHOSPHINE)IRIDIUM(I)
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin Et Al
    US 201201.15729A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin et al. (43) Pub. Date: May 10, 2012 (54) PROCESS FOR FORMING FILMS, FIBERS, Publication Classification AND BEADS FROM CHITNOUS BOMASS (51) Int. Cl (75) Inventors: Ying Qin, Tuscaloosa, AL (US); AOIN 25/00 (2006.01) Robin D. Rogers, Tuscaloosa, AL A6II 47/36 (2006.01) AL(US); (US) Daniel T. Daly, Tuscaloosa, tish 9.8 (2006.01)C (52) U.S. Cl. ............ 504/358:536/20: 514/777; 426/658 (73) Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF 57 ABSTRACT ALABAMA, Tuscaloosa, AL (US) (57) Disclosed is a process for forming films, fibers, and beads (21) Appl. No.: 13/375,245 comprising a chitinous mass, for example, chitin, chitosan obtained from one or more biomasses. The disclosed process (22) PCT Filed: Jun. 1, 2010 can be used to prepare films, fibers, and beads comprising only polymers, i.e., chitin, obtained from a suitable biomass, (86). PCT No.: PCT/US 10/36904 or the films, fibers, and beads can comprise a mixture of polymers obtained from a suitable biomass and a naturally S3712). (4) (c)(1), Date: Jan. 26, 2012 occurring and/or synthetic polymer. Disclosed herein are the (2), (4) Date: an. AO. films, fibers, and beads obtained from the disclosed process. O O This Abstract is presented solely to aid in searching the sub Related U.S. Application Data ject matter disclosed herein and is not intended to define, (60)60) Provisional applicationpp No. 61/182,833,sy- - - s filed on Jun.
    [Show full text]
  • 1.Development and Validation Of
    International Journal Of Advanced Research In Medical & Pharmaceutical Sciences (IJARMPS-ISSN-2455-6998) Volume.4,Issue.12,December.2019 DEVELOPMENT AND VALIDATION OF KETOCONAZOLE BY RP-HPLC MOODU BALU*,Dr. SANJEEV KUMAR SUBUDHI,SHAIK ZUBAIR, S. NAVYA, RUHEENA NAAZ, SIRIMALLA.MOUNIKA. Department of Pharmaceutical Analysis, Talla padmavathi pharmacy college , urus, kareemabad, warangal,506002. ABSTRACT : The objective of the present research work was to develop a innovative, simple, and economic method for estimation of Ketoconazole in bulk and dosage form by RP-HPLC.The chromatographic conditions were performed on Phenomenex Luna C18, 100A, 5µm, 250mmx4.6mm i.d.as stationary phase and mobile phase was prepared with a mixture of Acetonitrile : 0.2% triethylamine (pH-6.5) = 70:30 (pH-6.5) flow 1.0 ml/min, with Injection Volume 10µl, at detection wavelength 243 nm and run time at 5.0 min.The analytical method is valid for estimation of Ketoconazole over a range of 10µg/ml–50 µg/ml. The results of system suitability test, linearity, precision and accuracy, robustness, specificity, LOD and LOQ and stabilities presented in this report are within the acceptance range.A specific, sensitive, economic method estimation of Ketoconazole has been developed based on ICH Guidelines with bulk and dosage forms. Key Words: Ketoconazole , HPLC, Method Development, ICH, Validation, Accuracy, Precision. I.INTRODUCTION Ketoconazole is a lipophilic imidazole derivative appears as white to off white crystalline powder. The drug is not miscible in water, miscible in strong bases and soluble to a low extent in strong acid, having molecular weight of 531.44. It is a feeble base, having acid dissociation constant values of 6.51 and 2.94, it contains five- membered azole ring emboding two nitrogen atoms.[1-4] It is a chiral drug containing a racemic (1:1) mixture of enantiomers of the cis configuration.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,636.405 B2 Tamarkin Et Al
    USOO9636405B2 (12) United States Patent (10) Patent No.: US 9,636.405 B2 Tamarkin et al. (45) Date of Patent: May 2, 2017 (54) FOAMABLE VEHICLE AND (56) References Cited PHARMACEUTICAL COMPOSITIONS U.S. PATENT DOCUMENTS THEREOF M (71) Applicant: Foamix Pharmaceuticals Ltd., 1,159,250 A 1 1/1915 Moulton Rehovot (IL) 1,666,684 A 4, 1928 Carstens 1924,972 A 8, 1933 Beckert (72) Inventors: Dov Tamarkin, Maccabim (IL); Doron 2,085,733. A T. 1937 Bird Friedman, Karmei Yosef (IL); Meir 33 A 1683 Sk Eini, Ness Ziona (IL); Alex Besonov, 2,586.287- 4 A 2/1952 AppersonO Rehovot (IL) 2,617,754. A 1 1/1952 Neely 2,767,712 A 10, 1956 Waterman (73) Assignee: EMY PHARMACEUTICALs 2.968,628 A 1/1961 Reed ... Rehovot (IL) 3,004,894. A 10/1961 Johnson et al. (*) Notice: Subject to any disclaimer, the term of this 3,062,715. A 1 1/1962 Reese et al. tent is extended or adiusted under 35 3,067,784. A 12/1962 Gorman pa 3,092.255. A 6/1963 Hohman U.S.C. 154(b) by 37 days. 3,092,555 A 6/1963 Horn 3,141,821 A 7, 1964 Compeau (21) Appl. No.: 13/793,893 3,142,420 A 7/1964 Gawthrop (22) Filed: Mar. 11, 2013 3,144,386 A 8/1964 Brightenback O O 3,149,543 A 9/1964 Naab (65) Prior Publication Data 3,154,075 A 10, 1964 Weckesser US 2013/0189193 A1 Jul 25, 2013 3,178,352.
    [Show full text]